Literature DB >> 20675008

Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy.

Ankur Gupta1, Radha K Dhiman, Savita Kumari, Satyavati Rana, Ritesh Agarwal, Ajay Duseja, Yogesh Chawla.   

Abstract

BACKGROUND & AIMS: Minimal hepatic encephalopathy (MHE) is the mildest form in the spectrum of hepatic encephalopathy. This cross-sectional study was carried out to elucidate the role of bacterial overgrowth of the small intestine and delayed intestinal transit among patients with MHE.
METHODS: Two-hundred-thirty patients with cirrhosis were screened; 102 patients (44.4%) who met the eligibility criteria were included in the study. MHE was diagnosed when the psychometric hepatic encephalopathy score was ≤-5. All patients underwent a glucose breath test for small intestinal bacterial overgrowth (SIBO) and lactulose breath test for oro-cecal transit time (OCTT).
RESULTS: Fifty-seven (55.9%) patients with cirrhosis had MHE. Among these patients with MHE, 22 (38.6%) had SIBO, while 4 (8.9%) without MHE had SIBO (p = 0.001). The prevalence of SIBO was higher in patients with CTP classes B and C (69.2%) compared to those in CTP class A (30.8%); p = 0.054. OCTT was significantly prolonged in patients who had SIBO than in those who did not have SIBO (p<0.0001). Univariate analysis demonstrated that increased age, female gender, low educational status, low albumin, presence of SIBO, and prolonged OCTT were associated with the presence of MHE. Multivariate analysis demonstrated SIBO as the only factor associated with MHE.
CONCLUSIONS: Our study conclusively demonstrates high prevalence of SIBO in patients with cirrhosis with MHE. This study gives the rationale of treatment directed against SIBO and gut dysmotility, which may include non-absorbable antibiotics such as rifaximin, probiotics, and prokinetics.
Copyright © 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20675008     DOI: 10.1016/j.jhep.2010.05.017

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  68 in total

Review 1.  Advances in the evaluation and management of minimal hepatic encephalopathy.

Authors:  Jennifer Y Montgomery; Jasmohan S Bajaj
Journal:  Curr Gastroenterol Rep       Date:  2011-02

2.  Diagnosis: Intestinal inflammation--key to complications in cirrhosis?

Authors:  Ravi K Prakash; Kevin D Mullen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-01       Impact factor: 46.802

3.  Answers to multiple choice questions.

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2012-12

Review 4.  Alcoholic liver disease: the gut microbiome and liver cross talk.

Authors:  Phillipp Hartmann; Caroline T Seebauer; Bernd Schnabl
Journal:  Alcohol Clin Exp Res       Date:  2015-05       Impact factor: 3.455

5.  Effects of SIBO and rifaximin therapy on MHE caused by hepatic cirrhosis.

Authors:  Yuying Zhang; Yikuan Feng; Bin Cao; Qiang Tian
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 6.  Gut microbiota: its role in hepatic encephalopathy.

Authors:  Rahul Rai; Vivek A Saraswat; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2014-12-16

Review 7.  Minimal hepatic encephalopathy impairs quality of life.

Authors:  Swastik Agrawal; Sridharan Umapathy; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2014-12-04

Review 8.  Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis.

Authors:  Valerio Giannelli; Vincenza Di Gregorio; Valerio Iebba; Michela Giusto; Serena Schippa; Manuela Merli; Ulrich Thalheimer
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

9.  Small intestinal bacterial overgrowth in cirrhosis: systematic review and meta-analysis.

Authors:  Roman Maslennikov; Chavdar Pavlov; Vladimir Ivashkin
Journal:  Hepatol Int       Date:  2018-10-04       Impact factor: 6.047

10.  Influence of percutaneous local therapy for hepatocellular carcinoma on gastric function.

Authors:  Mitsuyoshi Kobayashi; Fumihiko Kinekawa; Kazuya Matsuda; Shintaro Fujihara; Noriko Nishiyama; Takako Nomura; Joji Tani; Hisaaki Miyoshi; Hideki Kobara; Akihiro Deguchi; Hirohito Yoneyama; Hirohito Mori; Tsutomu Masaki
Journal:  World J Gastroenterol       Date:  2013-03-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.